X

Trial Profile

Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
Indications Hodgkin's disease
Focus Therapeutic Use

Most Recent Events

31 May 2023 Planned End Date changed from 1 Sep 2021 to 1 Oct 2024.
14 Dec 2021 Updated results after extended follow-up of patients (median 33.1 months), and results of correlative studies analyzing 9p24.1 CNAs and PD-1 pathway expression, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
01 Jul 2020 Planned End Date changed from 1 Sep 2020 to 1 Sep 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com